NYSE:ZOMZomedica Pharmaceuticals Corp (NYSEAMERICAN) Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Zomedica Pharmaceuticals Corp (NYSEAMERICAN) Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Share Today's Range N/A50-Day Range$0.15MA: $0.18▼$0.2652-Week Range N/AVolume26.33 million shsAverage Volume46.86 million shsMarket Capitalization$25.53 millionP/E RatioN/ADividend YieldN/ABeta-0.01 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs. It is also developing ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. The company has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. Zomedica Pharmaceuticals Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingZomedica Pharmaceuticals Corp (NYSEAMERICAN) has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $0.50, Zomedica Pharmaceuticals Corp (NYSEAMERICAN) has a potential upside of ∞ from its current price of $0.00.Amount of Analyst CoverageZomedica Pharmaceuticals Corp (NYSEAMERICAN) has only been the subject of 1 research reports in the past 90 days. Previous Next 2.2 Community Rank Outperform VotesZomedica Pharmaceuticals Corp (NYSEAMERICAN) has received 152 “outperform” votes. (Add your “outperform” vote.)Underperform VotesZomedica Pharmaceuticals Corp (NYSEAMERICAN) has received 200 “underperform” votes. (Add your “underperform” vote.)Community SentimentZomedica Pharmaceuticals Corp (NYSEAMERICAN) has received 56.82% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Zomedica Pharmaceuticals Corp (NYSEAMERICAN) and other stocks. Vote “Outperform” if you believe ZOM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ZOM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldZomedica Pharmaceuticals Corp (NYSEAMERICAN) does not currently pay a dividend.Dividend GrowthZomedica Pharmaceuticals Corp (NYSEAMERICAN) does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zomedica Pharmaceuticals Corp (NYSEAMERICAN) insiders have bought more of their company's stock than they have sold. Specifically, they have bought $100,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders51.80% of the stock of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.77% of the stock of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) are expected to grow in the coming year, from ($0.04) to ($0.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) is -1.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) is -1.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.07 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:ZOM Previous Symbol CUSIPN/A CIK1684144 Webwww.zomedica.com Phone734-369-2555Debt Debt-to-Equity RatioN/A Current Ratio1.20 Quick Ratio1.20Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.09) per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)($0.19) Net Income$-19,780,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-166.87%Miscellaneous EmployeesN/A Outstanding Shares166,540,000Market Cap$25.53 million Next Earnings Date8/13/2020 (Estimated) OptionableNot Optionable 30 days | 90 days | 365 days | Advanced Chart Receive ZOM News and Ratings via Email Sign-up to receive the latest news and ratings for ZOM and its competitors with MarketBeat's FREE daily newsletter. Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN)? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN). When is Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s next earnings date? Zomedica Pharmaceuticals Corp (NYSEAMERICAN) is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Zomedica Pharmaceuticals Corp (NYSEAMERICAN). How were Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s earnings last quarter? Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) posted its earnings results on Monday, May, 11th. The company reported ($0.02) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.02). View Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s earnings history. What price target have analysts set for ZOM? 1 Wall Street analysts have issued 1 year price targets for Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s shares. Their forecasts range from $0.50 to $0.50. On average, they expect Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s stock price to reach $0.50 in the next twelve months. View analysts' price targets for Zomedica Pharmaceuticals Corp (NYSEAMERICAN). Has Zomedica Pharmaceuticals Corp (NYSEAMERICAN) been receiving favorable news coverage? Media headlines about ZOM stock have trended very positive this week, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Zomedica Pharmaceuticals Corp (NYSEAMERICAN) earned a news sentiment score of 4.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news about Zomedica Pharmaceuticals Corp (NYSEAMERICAN). Who are some of Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s key competitors? Some companies that are related to Zomedica Pharmaceuticals Corp (NYSEAMERICAN) include Evoke Pharma (EVOK), TapImmune (MRKR), Gemphire Therapeutics (GEMP), CTI BioPharma (CTIC), Galmed Pharmaceuticals (GLMD), Recro Pharma (REPH), OncoSec Medical (ONCS), AcelRx Pharmaceuticals (ACRX), Lipocine (LPCN), resTORbio (TORC), VERONA PHARMA P/S (VRNA), Oramed Pharmaceuticals (ORMP), Adamis Pharmaceuticals (ADMP), Conatus Pharmaceuticals (CNAT) and Aravive (ARAV). View all competitors. What other stocks do shareholders of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zomedica Pharmaceuticals Corp (NYSEAMERICAN) investors own include Protalix Biotherapeutics (PLX), Agile Therapeutics (AGRX), Crispr Therapeutics (CRSP), VBI Vaccines (VBIV), Acasti Pharma (ACST), Amarin (AMRN), Anavex Life Sciences (AVXL), Clearside Biomedical (CLSD), Allena Pharmaceuticals (ALNA) and Aileron Therapeutics (ALRN). Who are Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s key executives? Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s management team includes the following people: Mr. Gerald L. Solensky Jr., Chairman, CEO & Pres (Age 44)Dr. Stephanie Morley DVM, COO & VP of Product Devel. (Age 43)Mr. Robert W. DiMarzo, Exec. VP of Global Strategy (Age 61)Mr. Shameze Rampertab B.Sc. MBA, CA, CPA, CFO, Corp. Sec. & Director (Age 51)Mr. Bruk Herbst, Chief Commercial Officer (Age 49) What is Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s stock symbol? Zomedica Pharmaceuticals Corp (NYSEAMERICAN) trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZOM." Who are Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s major shareholders? Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Clear Creek Financial Management LLC (0.37%). Company insiders that own Zomedica Pharmaceuticals Corp (NYSEAMERICAN) stock include James Lebar and Johnny D Powers. View institutional ownership trends for Zomedica Pharmaceuticals Corp (NYSEAMERICAN). Which institutional investors are buying Zomedica Pharmaceuticals Corp (NYSEAMERICAN) stock? ZOM stock was acquired by a variety of institutional investors in the last quarter, including Clear Creek Financial Management LLC. View insider buying and selling activity for Zomedica Pharmaceuticals Corp (NYSEAMERICAN). How do I buy shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN)? Shares of ZOM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. How big of a company is Zomedica Pharmaceuticals Corp (NYSEAMERICAN)? Zomedica Pharmaceuticals Corp (NYSEAMERICAN) has a market capitalization of $0.00. The company earns $-19,780,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. What is Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s official website? The official website for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) is www.zomedica.com. How can I contact Zomedica Pharmaceuticals Corp (NYSEAMERICAN)? Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s mailing address is 100 PHOENIX DRIVE SUITE 190, ANN ARBOR MI, 48108. The company can be reached via phone at 734-369-2555 or via email at [email protected] This page was last updated on 8/8/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
